MCLEAN, Va., March 3, 2014 (GLOBE NEWSWIRE) -- Personalized Cancer Therapy, Inc. (d.b.a. Perthera), a precision cancer therapy firm, today announced that Subha Madhavan, PhD, a recognized leader in data science, clinical informatics and health information technology, has joined the company as chief data officer.
In her role, Dr. Madhavan will be responsible for strategic planning, the organization's data analytic framework, data standards as well as quality control of data. Among other initiatives, she will be working closely with the chief information officer to develop data analytic and reporting advances to the Perthera Expert System.
"I joined Perthera because I truly believe that leadership understands the way all oncologists will treat cancer in the future," says Dr. Madhavan. "As the only company to pair proteomics and phosphoproteomics with targeted genomic analysis, Perthera provides oncologists with a complete picture of a cancer's molecular landscape and the best available therapy options, allowing them to recommend the most effective treatment."
Dr. Madhavan currently serves as the director of the Innovation Center for Biomedical Informatics (ICBI) at the Georgetown University Medical Center and an associate professor of Oncology. She is responsible for several biomedical informatics efforts including the Georgetown Database of Cancer (G-DOC) a resource for both researchers and clinicians to realize the goals of personalized medicine, the National Cancer Institute (NCI) In Silico Research Center for Excellence, and co-directs Lombardi Cancer Center's Biostatistics and Bioinformatics shared resource.
She leads the Biomedical Informatics program of the Georgetown-Howard Universities CTSA. In this role, she has enabled access to more than 2.5 million patient records from 10 MedStar Health hospitals to translational researchers. She was the principal investigator on the Breast and Colon Cancer Family Registries data center that coordinates public health and epidemiology data across twelve sites in the United States, Australia and Canada. More recently, she has partnered with the Food & Drug Administration (FDA) on the Center for Excellence in Regulatory Science program to develop evidence bases for pharmacogenomics and vaccine safety.
Dr. Madhavan has a Master of Science in information technology from University of Maryland and a Ph.D. in molecular biology and biological sciences from the Uniformed Services University for the Health Sciences through a highly ranked Indo-US collaborative program.
"As personalized medicine is revolutionizing therapy treatments for cancer, Subha's background in data science and clinical informatics is a remarkable asset," says Perthera Chairman, Co-Founder and CEO Dendy Young. "We're pleased to have Subha join our dedicated team of scientific professionals as we help find new hope for advanced stage cancer patients."
Based in McLean, Virginia, Personalized Cancer Therapy, Inc. (d.b.a. Perthera) offers a concierge service that helps oncologists identify the best treatment options for patients employing chemotherapy to fight cancer. The company uses targeted molecular testing and its proprietary Perthera Expert System of molecular cancer profiles to recommend the latest treatment therapies individualized for each patient and his or her physician. For more information, visit www.perthera.com, like us on Twitter, or follow us on Facebook and YouTube.